Streetbeat News

Products Services

NPCE

NeuroPace has announced enhancements to its RNS System, designed to streamline care. The upgraded nSight Platform improves clinicians' ability to track, review, and evaluate patient data. The 'Simple Set Programming' feature enables direct programming set transfer to the RNS Tablet. The FDA has approved a smaller, portable, and simpler tablet remote monitor with wireless connectivity.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:07 pm

KURA

Kura Oncology has announced results from a study of Tipifarnib in patients with HRAS mutant HNSCC, showing meaningful antitumor activity. The data supports the rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indications. The results will be presented at the 2023 ESMO Congress.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:06 pm

YMAB

Y-mAbs Therapeutics has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for CD38-SADA. This clearance allows the company to proceed with clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:05 pm

BGNE

BeiGene announced that its Phase 3 RATIONALE 315 trial met primary endpoints for tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer. The data showed 56.2% of patients achieved major pathological response, versus 15.0% with neoadjuvant chemotherapy alone. Also, 40.7% of patients achieved the key secondary endpoint of pathological complete response, compared to 5.7% with neoadjuvant chemotherapy alone.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:05 pm

LXRX

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlighted two studies demonstrating the positive financial impact of INPEFA (sotagliflozin), recently approved by the FDA for heart failure treatment. The studies, presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting, showed that while INPEFA increased pharmacy costs, it reduced medical costs due to lower readmission rates and fewer emergency department visits. The studies also concluded that INPEFA is a cost-effective treatment for heart failure among patients with type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:03 pm

RYTM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has presented data from its long-term extension study of setmelanotide, showing sustained and deepened BMI reduction in patients with hypothalamic obesity at one year. The study showed a mean BMI reduction of 25.5% in patients with hypothalamic obesity, and three of 11 pediatric patients achieved normal weight at one year. The company also presented data showing clinically relevant weight reductions in patients with Bardet-Biedl syndrome and POMC or LEPR deficiency obesity.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:02 pm

RCUS

Arcus Biosciences (NYSE:RCUS) will present data from the ongoing Phase 2 EDGE-Gastric study at the ASCO Monthly Plenary Series on November 7, 2023. The study evaluates the combination of domvanalimab and zimberelimab in patients with advanced gastrointestinal cancers. Arcus will also report its Q3 2023 financial results and host a conference call on the same day.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:01 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained event-free survival and promising overall survival trends with three cycles of Opdivo in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer. The results showed a greater reduction in the risk of disease recurrence, progression or death than chemotherapy alone, regardless of PD-L1 expression levels. The results will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:51 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced results from the Phase 3 CheckMate -901 trial, where Opdivo in combination with cisplatin-based chemotherapy demonstrated significant improvements in overall survival and progression-free survival for patients with unresectable or metastatic urothelial carcinoma. The treatment reduced the risk of death by 22% and showed a tolerable safety profile. The data will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:49 pm

NFLX

TTWO

Netflix Inc (NASDAQ:NFLX) is set to report Q3 financial results, with analysts expecting revenue of $8.537 billion, an increase from $7.926 billion in the same quarter last year. The company has missed revenue estimates in five of the last seven quarters. Earnings per share are expected to be $3.47, up from last year’s $3.10. Analysts are watching for password sharing, advertising, margins, video games, sports and artificial intelligence. Netflix has also held discussions with Take-Two Interactive Software (NASDAQ:TTWO) about licensing a game from the “Grand Theft Auto” franchise.

Portfolio Pulse from Chris Katje

October 17, 2023 | 7:36 pm